These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28849241)

  • 1. A novel chalcone-based molecule, BDP inhibits MDA‑MB‑231 triple-negative breast cancer cell growth by suppressing Hsp90 function.
    Oh YJ; Seo YH
    Oncol Rep; 2017 Oct; 38(4):2343-2350. PubMed ID: 28849241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
    Oh YJ; Park SY; Seo YH
    Oncol Rep; 2018 Apr; 39(4):1775-1782. PubMed ID: 29436674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
    Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
    Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
    Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
    Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
    Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
    Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Cho TM; Kim JY; Kim YJ; Sung D; Oh E; Jang S; Farrand L; Hoang VH; Nguyen CT; Ann J; Lee J; Seo JH
    Cancer Lett; 2019 Apr; 447():141-153. PubMed ID: 30703411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
    Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM
    Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
    Friedland JC; Smith DL; Sang J; Acquaviva J; He S; Zhang C; Proia DA
    Invest New Drugs; 2014 Feb; 32(1):14-24. PubMed ID: 23686707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
    Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
    J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
    Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
    Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
    Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
    J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
    Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
    BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
    Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
    Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
    Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
    Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death.
    Hsu KW; Huang CY; Tam KW; Lin CY; Huang LC; Lin CL; Hsieh WS; Chi WM; Chang YJ; Wei PL; Chen ST; Lee CH
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
    Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
    Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
    Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
    Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
    Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.